Village Farms Intlの空売り状況は、投資家がVillage Farms Intlの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Village Farms Intl (NASDAQ:VFF) 株価情報, 空売り情報

Village Farms Intl

Village Farms International Inc owns and operates intensive agricultural greenhouse facilities in British Columbia and Texas, where it produces, markets and sells tomatoes, bell peppers and cucumbers. Its wholly owned subsidiary, Pure Sunfarms, is a vertically integrated licensed producer and supplier of cannabis products sold to other licensed providers and provincial governments across Canada and internationally. The Company's wholly owned subsidiary, Balanced Health, develops and sells, cannabidiol (CBD) based products including ingestible, edible and topical applications. The Company has identified four operating segments - Produce, Cannabis-Canada, Cannabis-U.S. and Energy. The company makes majority of its revenue from the Produce segment.

Village Farms International, Inc. - Common Shares

Village Farms International Inc

News

FORR

Forrester Research Announced 6% Workforce Reduction, Expects Pre-Tax Expenses $5.2M-$5.6M

Bank of America Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>) will release earnings for its fourth quarter, before the <a href="https://www.benzinga.com/quote/BAC/earnings">opening bell on Thursday, Jan. 16.</a>
Analysts expect the Charlotte, North Carolina-based company to report quarterly earnings at 77 cents per share. That&#8217;s up from 35 cents per share in the year-ago period. According to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>, Bank of America projects quarterly revenue of $25.09 billion, compared to $21.96 billion a year earlier.
On Jan. 7, UBS analyst Erika Najarian upgraded Bank of America from Neutral to Buy and announced a $53 price target.
With the recent buzz around Bank of America, some investors may be eyeing potential gains from the company's dividends too. Bank of America currently offers an annual dividend yield of 2.25%, or a quarterly dividend of 26 cents per share ($1.04 a year).
To figure out how to earn $500 monthly from Bank of America, we start with the yearly target of $6,000 ($500 x 12 months).
Next, we take this amount and divide it by Bank of America's $1.04 dividend: $6,000 / $1.04 = 5,769 shares.
So, an investor would need to own approximately $266,585 worth of Bank of America, or 5,769 shares to generate a monthly dividend income of $500.
Assuming a more conservative goal of $100 monthly ($1,200 annually), we do the same calculation: $1,200 / $1.04 = 1,154 shares, or $53,326 to generate a monthly dividend income of $100.
Note that dividend yield can change on a rolling basis, as the dividend payment and the stock price both fluctuate over time.
The dividend yield is calculated by dividing the annual dividend payment by the current stock price. As the stock price changes, the dividend yield will also change.
For example, if a stock pays an annual dividend of $2 and its current price is $50, its dividend yield would be 4%. However, if the stock price increases to $60, the dividend yield would decrease to 3.33% ($2/$60).
Conversely, if the stock price decreases to $40, the dividend yield would increase to 5% ($2/$40).
Further, the dividend payment itself can also change over time, which can also impact the dividend yield. If a company increases its dividend payment, the dividend yield will increase even if the stock price remains the same. Similarly, if a company decreases its dividend payment, the dividend yield will decrease.
BAC Price Action: Shares of Bank of America gained by 0.3% to close at $46.21 on Wednesday.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/25/01/42900074/how-to-earn-500-a-month-from-synovus-financial-stock-ahead-of-q4-earnings">How To Earn $500 A Month From Synovus Financial Stock Ahead Of Q4 Earnings</a></li>
</ul>
Image: Shutterstock

Earnings

Long Ideas

Markets

Trading Ideas

How To Earn $500 A Month From Bank of America Stock Ahead Of Q4 Earnings

Findings show significant brain activity after a single 20mg dose of SP-624 in healthy subjects
Phase 2b/3 study of SP-624 in major depressive disorder is underway
SP-624 has the potential to be the first treatment specifically for females with Major Depression
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.arrivobio.com%2F&amp;esheet=54176223&amp;newsitemid=20250110201020&amp;lan=en-US&amp;anchor=Arrivo+BioVentures&amp;index=1&amp;md5=b26643e71e80d6b6dbb548fa286adb84">Arrivo BioVentures</a> today announced positive data from its SP-624-103 study evaluating the impact of SP-624's novel epigenetic mechanism of action on neurological pathways. The findings provide insights into the potential antidepressant and cognitive effects of SP-624, a SIRT6 activator that may be the first treatment specifically for females with Major Depression based on previous studies.
Arrivo's SP-624-103 study is a double blind, placebo-controlled study with three cohorts. Cohort 1 is comprised of 12 healthy subjects (8 active, 4 placebo) who received 20mg of SP-624 over a 15-day dosing period. Assessments, including quantitative EEG (qEEG) and <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Ffireflyneuro.com%2F&amp;esheet=54176223&amp;newsitemid=20250110201020&amp;lan=en-US&amp;anchor=Firefly+Neuroscience%26%238217%3Bs&amp;index=2&amp;md5=faf584bd97e07c7f189d793410dbf3cb">Firefly Neuroscience's</a> ((<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;,%20url=https%3A%2F%2Ffinance.yahoo.com%2Fquote%2FAIFF%2F&amp;,%20esheet=54176223&amp;,%20newsitemid=20250110201020&amp;,%20lan=en-US&amp;,%20anchor=NASDAQ%3A+AIFF&amp;,%20index=3&amp;,%20NASDAQ:%3Ca%20class=">AIFF</a>) brain network analytics (BNA&#x2122;), were performed at Day One and Day 15 pre- and post-dose. Cohort 2 is actively enrolling 12 patients diagnosed with major depressive disorder (MDD). The subject composition of the 3rd cohort will be determined after the completion of the second cohort.
Cohort 1 results of the SP-624-103 study include:
<ul>
<li>Subjects showed an increase in beta power, particularly in the frontal-central regions compared to patients taking placebo after a single dose, suggesting enhanced synaptic plasticity and neuronal connectivity.</li>
<li>Subjects showed a decrease in delta power. This is important as increases in delta activity are often associated with reduced cortical arousal and depressive states.</li>
<li>Evoked potential response findings suggest enhanced neural efficiency in early perceptual processing and improved decision-making speed and context updating.</li>
</ul>

Biotech

General

AIFF

Arrivo BioVentures Announces Brain Activity Increase With Single 20mg SP-624 Dose In Healthy Subjects; Phase 2b/3 Trial For Major Depression In Progress; Potential First Treatment For Females With Major Depression; Enhanced Synaptic Plasticity And Neuronal Connectivity Observed

Management

ROLR

High Roller Technologies Appoints Kristofer Muscat As Chief Operating Officer

<ul>
<li>The US FDA, Health Canada, European Medicines Authority, and the Australian Therapeutic Goods Administration authorized the Company's global, randomized Phase 3 study (INVINCIBLE-3) in Metastatic Soft Tissue Sarcoma &nbsp;</li>
<li>Twenty-three sites are currently contracted in the INVINCIBLE 3 study, and several sites have treated patients &nbsp;</li>
<li>Seven Swiss sites are activated in the Phase 2 (INVINCIBLE-4) study for early-stage, operable Triple Negative Breast Cancer ("TNBC"), and several patients have been treated</li>
</ul>
SHELTON, Conn., Jan. 10, 2025 /PRNewswire/ -- <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4335946-1&amp;h=1845873411&amp;u=https%3A%2F%2Fintensitytherapeutics.com%2F&amp;a=Intensity+Therapeutics%2C+Inc.">Intensity Therapeutics, Inc.</a>&nbsp;("Intensity" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTS#NASDAQ">INTS</a>), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, today announces a business update highlighting key achievements with its lead drug candidate INT230-6.&nbsp;

INTS

Intensity Announces Regulatory Approval For Phase 3 Sarcoma Study INVINCIBLE-3 Across US, Europe, Canada, Australia; 23 Sites Contracted. Phase 2 INVINCIBLE-4 Study For TNBC Activated In Switzerland; Demonstrates Over 95% Tumor Killing In Some Patients

NXTC

NextCure Doses First Patient Dosed In Phase 1 Study Of LNCB74 (For Treating Multiple Cancers

INZY

Inozyme Pharma Announces Interim Data For INZ-701 in Infants And Young Children wWth ENPP1 Deficiency, Showing Improvements From Baseline In Multiple Measures Of Disease

– Dosing of Sentinel (First) Participant in RLYB212 Phase 2 Clinical Trial Expected in 2Q 2025 –
– Initiation of RLYB116 Confirmatory PK/PD Study Expected in 2Q 2025, with Data Anticipated in 2H 2025 –
– REV102, an ENPP1 Inhibitor for the Treatment of Hypophosphatasia, to Enter IND-Enabling Studies in 2025 –
Rallybio Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RLYB#NASDAQ">RLYB</a>), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today highlighted its 2024 accomplishments and announced its anticipated key milestones for 2025.

RLYB

Rallybio Highlights 2024 Achievements; Announces 2025 Milestones, RLYB212 Phase 2 Participant Dosing In Q2 2025, RLYB116 PK/PD Study Launch In Q2 2025, REV102 IND-Enabling Studies Planned For 2025; FNAIT Study Screening To Conclude January 2025.

HC Wainwright &amp; Co. analyst Robert Burns maintains Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) with a Buy and raises the price target from $29 to $40.

Price Target

Analyst Ratings

EXEL

HC Wainwright & Co. Maintains Buy on Exelixis, Raises Price Target to $40

- 71 patients dosed in the potentially pivotal Phase 2 clinical study of firicabtagene autoleucel (firi-cel); Interim analysis results expected to be reported in 1H'25 -
- IND application for CRG-023, CARGO's tri-specific CAR T, cleared by the FDA; Phase 1 study enrollment expected to initiate mid-year 2025 -
- CARGO announces novel allogeneic platform based on a universal allogeneic-enabling vector intended to be paired with any new or existing CAR vector to create an allogeneic CAR T-cell therapy while leveraging existing autologous drug product processes -&nbsp; &nbsp;
 SAN CARLOS, Calif., Jan. 10, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=ARZMJrK8j2BjKZzS_L10hQx5YAo4VCSXKkxHEiE4gMCdpf6MR9EnLIv9y1XRPZkFK1RH_JTLy8h9_CM7AuErzA3FqHObWkzEp5_hPSseszA=">CARGO Therapeutics, Inc</a>. (NASDAQ:<a href="https://www.benzinga.com/stock/CRGX#NASDAQ">CRGX</a>), a clinical-stage biotechnology company positioned to advance next-generation, potentially curative cell therapies for cancer patients, today provided a corporate update and anticipated milestones for 2025.

CRGX

CARGO Therapeutics Reports 71 Patients Dosed In Phase 2 Firicabtagene Autoleucel Study; Interim Results Expected H1'25; FDA Clears IND For CRG-023, Phase 1 Enrollment Mid-2025; Announces Novel Allogeneic Platform For CAR T-Cell Therapy

CASH

CASK

CORRECTION: Heritage Distilling Ticker Is 'CASK'

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Heritage Distilling Board Approves Bitcoin Treasury Policy

Guidance

TD SYNNEX Sees Q1 Adj. EPS $2.65 - $3.15 vs $2.95 Est., Revenue $14.4B - $15.2B vs $14.769B Est.

The Company reported the following results on a preliminary and unaudited basis2:
<ul>
<li>Net sales for the fourth quarter increased 5.0% to $402.0 million</li>
<li>Constant currency net sales3 for the fourth quarter increased 6.0% to $405.9 million, with the United States ("U.S.") increasing 10.5% and Canada decreasing 0.2%</li>
<li>Comparable store sales for the fourth quarter increased 1.6%, with the U.S. increasing 4.7% and Canada decreasing 2.5%</li>
<li>Net sales for fiscal 2024 increased 2.5% to $1.54 billion</li>
<li>Constant currency net sales3 for fiscal 2024 increased 3.1% to $1.55 billion, with the U.S. increasing 6.7% and Canada decreasing 1.6%</li>
<li>Comparable store sales for fiscal 2024 decreased 0.1%, with the U.S. increasing 2.7% and Canada decreasing 4.0%</li>
</ul>
Based on the preliminary fourth quarter and fiscal 2024 net sales results outlined above, the Company reaffirms its previously provided fiscal 2024 Adjusted earnings before interest, taxes, depreciation and amortization ("Adjusted EBITDA")1 outlook of approximately $290 million to $300 million.

Company Reports Q4 Net Sales Up 5% To $402M; U.S. Sales Rise 10.5%, Canada Falls 0.2%; Fiscal 2024 Sales Up 2.5% To $1.54B; Reaffirms EBITDA Outlook Of $290M-$300M

HC Wainwright &amp; Co. analyst Andrew Fein maintains Catalyst Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRX#NASDAQ">CPRX</a>) with a Buy and raises the price target from $30 to $35.

CPRX

HC Wainwright & Co. Maintains Buy on Catalyst Pharmaceuticals, Raises Price Target to $35

-- Additional data from BROADWAY, BROOKLYN, and TANDEM to be presented throughout 2025; expected to support global regulatory filings for obicetrapib, including EMA submission in 2H25 by our partner Menarini –
-- Data from Phase 2 VINCENT trial expected by 2H25, which explores effect of obicetrapib alone and in combination with a PCSK9i on Lp(a) –
-- Focus on commercial readiness with manufacturing capacity establishment and inventory build-out --
-- Year end, unaudited, cash balance of $835 million following oversubscribed public offering in December 2024 --
NAARDEN, The Netherlands and MIAMI, Jan. 10, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAMS#NASDAQ">NAMS</a>), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease ("CVD") with elevated low-density lipoprotein cholesterol ("LDL-C"), for whom existing therapies are not sufficiently effective or well-tolerated, today provided an update on the obicetrapib clinical development program and outlined its strategic priorities for 2025.
NewAmsterdam is developing obicetrapib, an oral, low-dose, once-daily, and highly selective cholesteryl ester transfer protein ("CETP") inhibitor, alone or as a fixed-dose combination with ezetimibe, as preferred LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of cardiovascular disease with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated.&nbsp;The Company's global, pivotal Phase 3 clinical development program consists of four trials in over 12,250 patients.

NAMS

NewAmsterdam Pharma Outlines 2025 Strategy With Obicetrapib Focus; Expects EMA Filing In H2 2025, Unveils $835M Year-End Cash. Highlights: BROADWAY 33% LDL-C Reduction, TANDEM 49% Reduction, BROOKLYN 36% Reduction; PREVAIL Trial Ongoing. VINCENT & REMBRANDT Trials To Conclude In 2025, 2027.

INSM

Insmed Provides Outlook Ahead Of J.P. Morgan Healthcare Conference; Sees 2025 Global ARIKAYCE Revenues $405M-$425M

Preliminary unaudited fourth quarter 2024 net revenue expected to be approximately $12 million to $12.3 million, representing 99% growth over Q4 2023 at the mid-point of the range
Fourth quarter 2024 Gross-to-net (GTN) discount expected to be in the range of 18% to 19%
Preliminary unaudited full year 2024 net revenue expected to be approximately $36.2 million to $36.5 million, compared to $13.6 million for full year 2023
BURLINGTON, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCPH#NASDAQ">SCPH</a>) (the "Company"), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced preliminary results for the fourth quarter and full year 2024, including fourth quarter 2024 net FUROSCIX revenue and unaudited cash and cash equivalents.

SCPH

scPharmaceuticals Reports Preliminary Q4 Revenue Of $12M-$12.3M; FY24 Revenue Expected To Be $36.2M-$36.5M

HURC

Hurco Cos Q4 EPS $(0.23) Down From $0.36 YoY, Sales And Service Fees $53.7M Down From $66.11M YoY

<h3>Gainers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>)</td>
<td>SPDR Select Sector Fund - Energy Select Sector</td>
<td align="right">89.2000</td>
<td align="right">1.17</td>
<td align="right">1.32</td>
<td>33.1K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>)</td>
<td>SPDR Select Sector Fund - Utilities</td>
<td align="right">76.3900</td>
<td align="right">0.38</td>
<td align="right">0.49</td>
<td>13.8K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>)</td>
<td>SPDR Select Sector Fund - Consumer Discretionary</td>
<td align="right">223.3000</td>
<td align="right">0.29</td>
<td align="right">0.13</td>
<td>603</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>)</td>
<td>SPDR Select Sector Fund - Health Care</td>
<td align="right">140.5199</td>
<td align="right">0.09</td>
<td align="right">0.06</td>
<td>1.5K</td>
</tr>
</tbody>
</table>
<h3>Losers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>)</td>
<td>SPDR Select Sector Fund - Technology</td>
<td align="right">232.4200</td>
<td align="right">-1.460</td>
<td align="right">-0.63</td>
<td>23.4K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>)</td>
<td>SPDR Select Sector Fund - Financial</td>
<td align="right">48.2736</td>
<td align="right">-0.216</td>
<td align="right">-0.45</td>
<td>91.7K</td>
</tr>
</tbody>
</table>
<a href="https://pro.benzinga.com/?utm_source=insights">Pulled from Benzinga Pro data</a> this sector movers alert provides traders with a compiled way to read macro-level market trends. Investors garner a particular interest in sector movers to better determine sectors that are over- or under-performing to make better investing decisions on exchange-traded funds (ETFs) or individual tickers in those sectors. 
To read more about sector movers, <a href="https://www.benzinga.com/movers">click here</a>.

Sector ETFs

Pre-Market Outlook

Movers

ETFs

Select Sector SPDR-Consumer Discretionary

Leading And Lagging Sectors For January 10, 2025

Village Farms GAAP EPS of -$0.01 beats by $0.02, revenue of $83.37M beats by $2.8M

In a report released today, Eric Des Lauriers from Craig-Hallum maintained a Buy rating on Village Farms International (VFF – Research Report). The...

Craig-Hallum Sticks to Their Buy Rating for Village Farms International (VFF)

Village Farms International (VFF) Q3 2024 Earnings Conference Call Transcript

Avoid Canopy Growth

Village Farms International (VFF) has released an update. Village Farms International and Hemp for Victory have filed a motion to disqualify the DE...

Village Farms Challenges DEA's Role in Cannabis Rescheduling

The AgTech industry is transforming the agricultural landscape with innovations to boost productivity and sustainability. Given this backdrop, consider keeping an eye on agricultural technology stocks like Deere & Co. (DE), Corteva (CTVA), and Village Farms International (VFF). Read more… The agricultural technology (AgTech) sector is revolutionizing food production by integrating cutting-edge technologies such as Artificial Intelligence (AI), robotics, and precision farming. Leveraging AI, robotics, and data analytics, these firms are addressing global challenges like climate change and resource shortages.
Below, I have highlighted three agricultural technology firms: Deere &amp; Company (<a href="https://stocknews.com/stock/DE/">DE</a>), Corteva, Inc. (<a href="https://stocknews.com/stock/CTVA/">CTVA</a>), and Village Farms International, Inc. (<a href="https://stocknews.com/stock/VFF/">VFF</a>), which are well-positioned to capture the opportunity to enhance food production.
Under the Biden-Harris administration, the <a href="https://www.usda.gov/media/press-releases/2024/10/30/biden-harris-administration-makes-investments-strengthen-american">U.S. Department of Agriculture (USDA)</a> announced it would strengthen American farms and expand innovative domestic fertilizer production by awarding over $120 million to fund six fertilizer production projects.
Precision agriculture has gained traction, allowing farmers to monitor crop health and soil conditions with tools like sensors and drones. These technologies help minimize waste and maximize yields. <a href="https://www.gao.gov/products/gao-24-105962">Federal agencies support such innovations</a> and have implemented a conservation benefit for implementing such practices over the last few years.
The worldwide AgTech market is anticipated to reach <a href="https://explodingtopics.com/blog/agtech-market">$74.03 billion by 2034</a>, growing at a CAGR of 12.2%. Also, with sustainable agriculture becoming a global priority, these companies are positioned to benefit from long-term growth trends, providing solutions that address both economic and environmental challenges.
With that in mind, let's dig deeper into the fundamentals of the above-mentioned AgTech stocks in detail:
Deere &amp; Company (<a href="https://stocknews.com/stock/DE/">DE</a>)
DE engages in the manufacture and distribution of various equipment worldwide. The company operates through four segments: Production and Precision Agriculture; Small Agriculture and Turf; Construction and Forestry; and Financial Services. 
On October 23, DE introduced its next generation of SmartGrade technology on the 450, 550, and 650 P-Tier Small Dozers. This new technology rollout enables seamless upgradeability and also serves as a more enhanced management solution.
In the same month, DE announced an expansion to its Agriculture &amp; Turf training center and field site. This development supports both service and sales training and is viewed as an investment that advances the company's commitment to customer success through the support of John Deere's world-class dealer channel. 
DE's total <a href="https://www.investopedia.com/terms/r/revenue.asp">revenue</a> for the fourth quarter (ended October 27, 2024) amounted to $11.14 billion. The company's attributable net income came in at $1.25 billion and $4.55 per share.
Analysts expect DE's revenue for the first quarter (ending January 2025) to decline 32.9% year-over-year to $8.83 billion. However, the consensus EPS estimate of $3.93 for the same period indicates a 52.8% year-over-year decline.
Over the past nine months, the stock has surged 12.3%, closing the last trading session at $412.
DE's stance is apparent in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The stock has a B grade for Momentum. The POWR Ratings are calculated by considering 118 different factors, each weighted to an optimal degree.
Among the 79 stocks in the A-rated <a href="https://stocknews.com/category/industrial-machinery/">Industrial - Machinery</a> industry, it is ranked #61. <a href="https://stocknews.com/stock/DE/">Click here</a> to see the additional DE ratings (Growth, Value, Stability, Sentiment, and Quality).
Corteva, Inc. (<a href="https://stocknews.com/stock/CTVA/">CTVA</a>)
CTVA is a global pure-play agriculture company that provides seed and crop protection solutions focused on the agriculture industry. The company operates in two segments: Seed and Crop Protection.
On November 18, CTVA announced a partnership with BP p.l.c. (<a href="https://stocknews.com/stock/BP/">BP</a>) to develop a low-carbon intensity bio-feedstock joint venture. This collaboration would produce and deliver crop-based biofuel feedstocks to help meet the anticipated growth in demand for Sustainable Aviation Fuel (SAF). It will also help CTVA become part of the global decarbonization solution.
On September 17, CTVA announced a collaboration with Pairwise, a technology company pioneering the application of gene editing in food and agriculture. This collaboration is to accelerate the delivery of advanced gene editing solutions in agriculture. Under this agreement, CTVA will invest $25 million as equity investment in Pairwise, helping expand the reach and benefits of gene editing to a variety of staple and special corps.
For the nine-month period that ended on September 30, 2024, CTVA's net sales stood at $12.93 billion. Its non-GAAP operating EBITDA amounted to $2.85 billion, while its Seed segment's non-GAAP operating EBITDA grew 7.8% year-over-year to $2.13 billion. Also, its non-GAAP operating earnings per share came in at $2.24.
According to the company's financial guidance, CTVA forecasts fiscal year 2024 operating EBITDA in the range of $3.35 billion-$3.45 billion. In addition, it anticipates its free cash flow to be in the range of $1.50 billion-$2 billion.
The consensus revenue estimate of $4.06 billion for the fiscal fourth quarter (ending December 2024) represents a 9.6% increase year-over-year. The consensus EPS estimate of $0.32 for the same quarter indicates a 115.6% improvement year-over-year. The company has an impressive surprise history; it surpassed the consensus EPS estimates in three of the trailing four quarters.
The stock has gained 25.4% over the past year to close the last trading session at $58.88.
CTVA's POWR Ratings reflect this outlook. It is ranked #15 out of 24 stocks in the <a href="https://stocknews.com/category/agriculture/">Agriculture</a> industry. To see the other ratings of CTVA for Growth, Value, Momentum, Stability, Sentiment, and Quality, <a href="https://stocknews.com/stock/CTVA/">click here</a>.
Village Farms International, Inc. (<a href="https://stocknews.com/stock/VFF/">VFF</a>)
Headquartered in Delta, Canada, VFF produces, markets, and sells greenhouse-grown tomatoes, bell peppers, and cucumbers. The company is also a vertically integrated supplier of plant-based consumer packaged goods in the cannabis and cannabidiol (CBD) categories. It operates through four segments: Produce; Cannabis-Canada; Cannabis-U.S.; and Energy. 
On September 24, VFF announced the complete acquisition of Leli Holland, B.V. This transaction will allow VFF to permit legal recreational cannabis operations and also help expand its medicinal operations internationally.
On August 1, ROSE LifeScience Inc., majorly owned by VFF, received a Cannabis Research Licence from Health Canada under the Cannabis Act. This approval will enable ROSE to focus on advanced product innovations and developments in cannabis and validate value-added technologies.
During the third quarter that ended on September 30, 2024, VFF's sales increased 19.9% year-over-year to CAD83.37 million ($59.64 million). The company's gross profit came in at CAD15.71 million ($11.28 million), reflecting an increase of 7.4% from the prior year's quarter. In addition, its adjusted EBITDA amounted to CAD5.30 million ($3.79 million), reflecting an increase of 63.2% year-over-year.
Street expects VFF's revenue for the current year (ending December 2024) to increase 16.6% year-over-year to $333.74 million. For the fiscal year 2025, its revenue is expected to grow by 4.1% from the prior year to $347.40 million.
Shares of VFF have surged marginally year-to-date to close the last trading session at $0.79.
VFF's fundamentals are reflected in its POWR Ratings. The stock has a B grade for Growth. It is ranked #14 out of 24 stocks in the Agriculture industry.
Beyond what is stated above, we've also rated VFF for Value, Momentum, Stability, Sentiment, and Quality. Get all VFF's ratings <a href="https://stocknews.com/stock/VFF/">here</a>.
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>

<hr />
DE shares were trading at $439.35 per share on Thursday afternoon, up $34.39 (+8.49%). Year-to-date, DE has gained 11.10%, versus a 26.19% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: ShreyaRathi</h2> <img src='https:/wp-content/uploads/2024/10/0.jpeg' style="float:left; padding:5px;width:125px;"><a href="https://stocknews.com/authors/?author=shreya-rathi">More...</a>The post <a href=https://stocknews.com/news/de-ctva-vff-bp-3-agricultural-technology-firms-enhancing-food-production/>3 Agricultural Technology Firms Enhancing Food Production</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Agricultural Technology Firms Enhancing Food Production

SNDL Shows Continued Improved Financials And Free Cash Flow For Q3-2024

Tilray Brands May Bounce

Village Farms Set To Grow In 2025 With Dutch Cannabis Revenues

The latest announcement is out from Village Farms International ( ($VFF) ). Village Farms International, in conjunction with Hemp for Victory, has ...

Village Farms and Hemp for Victory Challenge DEA's Role in Marijuana Rescheduling

CRON

CTVA

SNDL

TLRY

VRNOF

Press Releases

Village Farms International Acquires Remaining Equity Ownership Interest in Leli Holland

Village Farms International Announces Participation at the Benzinga Cannabis Capital Conference in Chicago

Village Farms International Provides Update on Nasdaq Listing

Village Farms International to Report Q3/24 Results on November 7, 2024

Legal

Village Farms International Selected to Testify at Marijuana Rescheduling Hearing

Village Farms International Reports Strong Q3/24 Results

Super Toast Brings Consumers a New All-In-One Vape Experience

Village Farms International and Hemp for Victory File Joint Motion to Disqualify DEA from Oversight of Proposed Marijuana Rescheduling Process

Soar Brings Back The Canna Czar

Village Farms International and Hemp for Victory File Request for Reconsideration of Prior Motion to Disqualify DEA from Participation in Rescheduling Hearings

Comments

Village Farms Intl

空売り

Village Farms Intl (NASDAQ:VFF) 株価情報, 空売り情報

ニュース

パートナーシップ

ベンジンガ・グローバル